A monthly, source-rich summary of research and regulatory news around peptides and related therapies. We discuss publications and announcements — this is not usage, dosing or treatment advice. All substances supplied by Peplife are Research Use Only.
★ In this edition: two neoantigen vaccines and a level-headed BPC-157 review
The most striking development this month is the first positive phase 3 result for an individualised mRNA neoantigen vaccine in melanoma.
We also cover NeoVax, a personalised neoantigen peptide vaccine in glioblastoma, and a new review that soberly maps out the research status of BPC-157.
This is deliberately a short edition. We would rather have three items that rest entirely on verified sources than ten half-supported ones.
1. mRNA neoantigen vaccine reaches phase 3 in melanoma.
On 19 August 2026, Moderna and Merck announced that the phase 3 trial INTerpath-001 had met its primary objectives. The individualised mRNA neoantigen vaccine intismeran autogene (mRNA-4157 / V940), given together with the immunotherapy pembrolizumab, extended recurrence-free survival and the time to distant metastasis in surgically resected stage IIB to IV melanoma. A total of 1,137 people took part. It is the first positive late-stage result for an individualised neoantigen vaccine. Important context: this is an mRNA immunotherapy in clinical development, not a peptide from our range and not a product we offer. More in the pillar peptides in cancer research. Sources: STAT News and The American Journal of Managed Care, both 19 August 2026.
2. NeoVax: neoantigen peptide vaccine in glioblastoma.
Results from NeoVax were presented at the 2026 ASCO meeting: a personalised neoantigen vaccine that — unlike the mRNA vaccine above — consists of peptides. This phase 1 study enrolled 39 people with newly diagnosed glioblastoma; treatment was actually started in 37 of them, in combination with pembrolizumab. Vaccine-specific T cells were subsequently detectable in the blood and in brain and tumour tissue. Median overall survival was 36.9 months in participants with a methylated MGMT gene and 19.0 months with unmethylated MGMT, against historical reference values of 25.3 and 16.7 months respectively. Investigator David Reardon expressly pointed out that this is not a direct comparison: it is a small, non-randomised phase 1 study whose outcome must be confirmed in larger research. More in the pillar AI and the future of peptide design. Source: ecancer, report from ASCO 2026.
3. New review adds nuance to the status of BPC-157.
In 2026 the review “BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers” was published. The title summarises the content: the article explicitly treats BPC-157 as a research peptide and maps the biopharmaceutical challenges, formulation strategies and translational development barriers that stand between the laboratory and any eventual clinical application. Separately from this review, it still holds for BPC-157 that its effect in humans has not been confirmed in controlled clinical studies; the available evidence comes predominantly from preclinical research in animal and cell models. More in the pillar BPC-157 research. Source: PubMed Central, PMC13210877.
Regulatory context: nothing changes for the EU.
The broader regulatory line from our earlier editions remains unchanged. In the United States the FDA advisory process around compounding continues; in Europe, the EMA guideline on the development and manufacture of synthetic peptides has applied since 1 June 2026, setting requirements for medicinal product registration. None of that changes the RUO status of research peptides in the EU. More in the pillar the FDA and peptides.
Independently tested · RUO · Sources: STAT News, The American Journal of Managed Care, ecancer, PubMed Central.
Previous edition: Peptide Research Bulletin — August 2026.